Product Name | Pemetrexed Disodium Heptahydrate | LY231514 disodium heptahydrate |
---|---|
CAS | 357166-29-1 |
Formula | C20H33N5Na2O13 |
MW | 597.48 |
Appearance | White to off-white powder |
Storage condition | 4°C, sealed storage, away from moisture |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
500 mg | In-stock | ¥500.00 | Visible after login | |
1 g | In-stock | ¥800.00 | Visible after login | |
5 g | In-stock | ¥1280.00 | Visible after login |
Product Name | Pemetrexed Disodium Heptahydrate | LY231514 disodium heptahydrate |
---|---|
CAS | 357166-29-1 |
Formula | C20H33N5Na2O13 |
MW | 597.48 |
Appearance | White to off-white powder |
Storage condition | 4°C, sealed storage, away from moisture |
Pemetrexed disodium heptahydrate (LY231514; HSDB7316; LY-231514; HSDB-7316; Alimta), the heptahydrated disodium salt of Pemetrexed and a pyrimidine-based antifolate, is an antifolate and antimetabolite anticancer medication. It targets TS, DHFR, and GARFT with Ki values of 1.3 nM, 7.2 nM, and 65 nM, in that order. In a variety of tumor types, including malignant mesothelioma, NSCLC (non-small cell lung carcinoma), carcinomas of the breast, colorectum, uterine cervix, head and neck, and bladder, pemetrexed shows strong antitumor activity.
PMID: 9067281
PMID: 20548032 DOI: 10.4049/jimmunol.0900437